Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Women's Hair Loss: PP405 Gel Aims to Reactivate Dormant Hair Follicles
More Weight Loss Than Tirzepatide Alone? The EloraTZP Trade-Off
FDA Approves Ryzumvi Eye Drops: Can They Reduce the Need for Reading Glasses?
Could Ultrasound Reduce Chronic Migraine Days? A New Trial Targets the Brain
From a Melanoma Vaccine to Weekly Insulin: 9 Medical Advances
Could Ultrasound During Sleep Help Clear Alzheimer's-Linked Amyloid From the Brain?
Could a Shingles Shot Also Help Prevent Heart Attacks and Strokes?

今後の臨床試験

Clinical Research Jobs

More jobs

スポンサーと協力者

医学的状態

薬物療法

購読する